Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
F3 Platform Biologics Inc. maintains a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. The records indicate 1 pending office action, which represents the entirety of the company's current active prosecution. This single pending action suggests that the company is focusing its intellectual property efforts on a specific, singular application at this stage.
The prosecution environment for this portfolio is extremely narrow, featuring only 1 distinct examiner and 1 distinct art unit. This concentration means that the 1 pending office action is being reviewed in a highly localized manner. For practitioners, this indicates that the entire current prosecution strategy for F3 Platform Biologics Inc. is subject to the specific interpretations and procedural habits of a single examiner within one specialized unit.
WELLS, LAUREN QUINLAN is the busiest examiner for this portfolio, currently managing 1 busiest examiner pending action. Because this 1 action is the only one currently pending for the company, WELLS, LAUREN QUINLAN is responsible for the entirety of the company's active matters. The fact that 1 distinct examiner is paired with 1 distinct art unit reinforces the singular focus of the company's current patent office interactions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WELLS, LAUREN QUINLAN | 1 | 49.0% | +61.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18252149 | COMPOSITIONS AND METHODS FOR PREVENTING AND PROTECTING AGAINST DAMAGE IN CELLS AND TISSUES | WELLS, LAUREN QUINLAN | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18252149 | COMPOSITIONS AND METHODS FOR PREVENTING AND PROTECTING AGAINST DAMAGE IN CELLS AND TISSUES | WELLS, LAUREN QUINLAN | 1622 | §102§103§112DPOther | Non-Final OA | — | Pending | May 08, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialF3 Platform Biologics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Lauren Quinlan Wells has the most, with 1 of F3 Platform Biologics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.